At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Bevacizumab 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Centro de Investigación en. Enfermedades Infecciosas, Mexico·interventional·Posted Feb 16, 2011·Updated Jul 27, 2015
In Brief
A Phase 2 clinical trial evaluating Bevacizumab for Kaposi´s Sarcoma. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed. The purpose of this study is to compare the effectiveness of intralesional bevacizumab + HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with AIDS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKaposi´s Sarcoma
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedFeb 2011
Primary CompletionDec 2012
Study CompletionDec 2013
TodayJul 2026
First PostedFeb 16, 2011
Enrollment StartSep 1, 2010
Primary CompletionDec 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.4 years ago
Interventions
Bevacizumabdrug
Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3